Company Overview of The University of Massachusetts Medical School
55 Lake Avenue North
Worcester, MA 01655
Key Executives for The University of Massachusetts Medical School
Provost, Executive Deputy Chancellor and Dean of the School of Medicine
Director for Diabetes Center of Excellence and Division Chief of Diabetes
Director for the Cancer Center of Excellence
Senior Director of Human Stem Cell Bank & Registry
Compensation as of Fiscal Year 2014.
The University of Massachusetts Medical School Key Developments
Umass Medical School Consulting Division Announces Executive Changes
Feb 26 15
Commonwealth Medicine, the consulting division of UMass Medical School has named former state health care policy director Kimberly Haddad as the organization's new chief of staff. Haddad will help the organization as it serves as a consultant for both public and private agencies in 20 states, including Massachusetts, and 27 countries and territories to improve health and human service programs. The appointment completes a months-long search to replace Abigail Averbach, who has become the senior program director of data analytics at Commonwealth Medicine.
LYSOGENE Enters into Strategic Collaboration with University of Massachusetts Medical School and Auburn University
Feb 10 15
LYSOGENE announced that it has entered into a strategic collaboration with the University of Massachusetts Medical School (UMMS) and Auburn University (AU). Through the collaboration, LYSOGENE, UMMS and AU will develop IND-supporting preclinical studies in GM1-gangliosidosis, a rare, inherited disorder characterized by severe neurological impairment, using adeno-associated virus (AAV) gene therapy technology. The collaboration will combine LYSOGENE's translational and clinical expertise in gene therapy for CNS disorders with the unique preclinical expertise and infrastructure of UMMS and AU to design and test innovative AAV-based gene therapy approaches to treat GM1-gangliosidosis.
Voyager Therapeutics and The University of Massachusetts Medical School Announce Strategic Collaboration for Viral Vector Manufacturing
Dec 11 14
Voyager Therapeutics announced entered into a strategic collaboration with MassBiologics of the University of Massachusetts Medical School (UMMS). Through the collaboration, MassBiologics and Voyager Therapeutics will establish scalable processes for manufacturing recombinant adeno-associated viral (rAAV) vector products using current good manufacturing practices (cGMP). The collaboration will combine Voyager’s rAAV production technology platform with the manufacturing expertise and infrastructure of MassBiologics. Scientists from Voyager and MassBiologics will work together to establish Voyager’s proprietary third generation baculovirus/Sf9 process for the production of rAAV vectors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries